Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality

A Population-Based Study

  • Haroon, Nisha Nigil MD, DM, DNB, MSc
  • Paterson, J. Michael MSc
  • Li, Ping PhD
  • Inman, Robert D. MD
  • Haroon, Nigil MD, PhD, DM
Annals of Internal Medicine 163(6):p 409-416, September 15, 2015.

Background:

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis affecting the spine in young adults. It is associated with excess cardiovascular and cerebrovascular morbidity.

Objective:

To determine whether patients with AS are at increased risk for cardiovascular and cerebrovascular mortality.

Design:

Population-based retrospective cohort study using administrative health data.

Setting:

Ontario, Canada.

Patients:

21 473 patients with AS aged 15 years or older and 86 606 comparators without AS, matched for age, sex, and location of residence.

Measurements:

The primary outcome was a composite of cardiovascular and cerebrovascular death. Hazard ratios (HRs) for vascular death were calculated; adjusted for history of cancer, diabetes, dementia, inflammatory bowel disease, hypertension, chronic kidney disease, and peripheral vascular disease; and, among those aged 66 years or older, relevant drug therapies. Independent risk factors for vascular mortality were identified in patients with AS.

Results:

The mean age of patients with AS was 46 years, and 53% were male. Patients and comparators were followed for 166 920 and 686 461 patient-years, respectively. Adjusted HRs for vascular death in AS were 1.36 (95% CI, 1.13 to 1.65) overall, 1.46 (CI, 1.13 to 1.87) in men, and 1.24 (CI, 0.92 to 1.67) in women. Significant risk factors for vascular death were age; male sex; lower income; dementia; chronic kidney disease; peripheral vascular disease; and, among patients aged 65 years or older, lack of exposure to nonsteroidal anti-inflammatory drugs and statins.

Limitation:

Diagnosis codes for AS were not validated in Ontario.

Conclusion:

Ankylosing spondylitis is associated with increased risk for vascular mortality. A comprehensive strategy to screen and treat modifiable vascular risk factors in AS is needed.

Primary Funding Source:

The Arthritis Program, University Health Network, Toronto; and The Arthritis Society, Canada.

Copyright © 2015 American College of Physicians
View full text|Download PDF